The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Cathepsin K inhibitors for osteoporosis and potential off-target effects
Open accessAbstract
Cathepsin K is a highly potent collagenase and the predominant papain-like cysteine protease expressed in osteoclasts. Cathepsin K deficiencies in humans and mice have underlined the central role of this protease in bone resorption and, thus, have rendered the enzyme as an attractive target for anti-resorptive osteoporosis therapy. In the past decade, a lot of efforts have been made in developing highly potent, selective and orally applicable cathepsin K inhibitors. Some of these inhibitors have passed preclinical studies and are presently in clinical trials at different stages of advancement. The development of the inhibitors and preliminary results of the clinical trials revealed problems and lessons concerning the in situ specificity of the compounds and their tissue targeting. In this review, we briefly summarize the history of cathepsin K research and discuss the current development of cathepsin K inhibitors as novel anti-resorptives for the treatment of osteoporosis. We also discuss potential off-target effects of cathepsin K inhibition and alternative applications of cathepsin K inhibitors in arthritis, atherosclerosis, blood pressure regulation, obesity and cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tjäderhane, L., Buzalaf, M. A. R., Carrilho, M., & Chaussain, C. (2015) · Caries Research · doi:10.1159/000363582 · Cited by 2,306
Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy
Weinstein, R. S., Roberson, P. K., & Manolagas, S. C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802633 · Cited by 391
The expression of adipogenic genes is decreased in obesity and diabetes mellitus
Nadler, S. T., Stoehr, J. P., Schueler, K. L., Tanimoto, G., Yandell, B. S., & Attie, A. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.21.11371 · Cited by 386
Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis
Taleb, S., Lacasa, D., Bastard, J., Poitou, C., Cancello, R., Pelloux, V., Viguerie, N., Benis, A., Zucker, J., Bouillot, J., et al. (2005) · The FASEB Journal · doi:10.1096/fj.05-3673fje · Cited by 158 · cited 1×
“Given the involvement of cathepsin S in the development of atherosclerotic processes, cathepsin S is probably a plausible candidate to link obesity and cardiovascular diseases [127,128] but the mechanisms whereby enlarged adipose tissue affects vascular function remain poorly defined.”
Background
Cited by
Cysteine cathepsins and extracellular matrix degradation
Fonović, M., & Turk, B. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.03.017 · Cited by 345
Structure-based design of targeted covalent inhibitors
Lonsdale, R., & Ward, R. A. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00220c · Cited by 344
Targeting the lysosome in cancer
Piao, S., & Amaravadi, R. K. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12953 · Cited by 304
Bone metastasis in prostate cancer: emerging therapeutic strategies
Sturge, J., Caley, M. P., & Waxman, J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.67 · Cited by 256
Metadata
- Authors
- Brömme, D., & Lecaille, F.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2009-04-24
- Volume
- 18
- Issue
- 5
- Pages
- 585-600
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2166753714
- Cited by
- 216
- References
- 4
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cathepsin K inhibitors for osteoporosis and potential off-target effects. https://app.cochat.ai/papers/10.1517/13543780902832661
- The paper
- Brömme, D., & Lecaille, F. (2009). Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543780902832661
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.